OptiNose (NASDAQ:OPTN) is scheduled to be posting its quarterly earnings results after the market closes on Monday, August 12th. Analysts expect OptiNose to post earnings of ($0.75) per share for the quarter.
OptiNose (NASDAQ:OPTN) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.71) by $0.01. OptiNose had a negative return on equity of 81.04% and a negative net margin of 983.22%. The business had revenue of $4.48 million for the quarter, compared to analysts’ expectations of $4.35 million. On average, analysts expect OptiNose to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
OptiNose stock traded down $0.23 during midday trading on Monday, reaching $4.78. The stock had a trading volume of 2,772 shares, compared to its average volume of 239,537. OptiNose has a 12 month low of $4.95 and a 12 month high of $22.96. The business has a 50-day moving average of $6.75. The firm has a market cap of $206.73 million, a price-to-earnings ratio of -1.82 and a beta of 0.91. The company has a debt-to-equity ratio of 0.79, a current ratio of 6.95 and a quick ratio of 6.74.
A number of equities research analysts recently issued reports on the company. ValuEngine upgraded OptiNose from a “hold” rating to a “buy” rating in a research note on Thursday. Piper Jaffray Companies set a $29.00 price target on OptiNose and gave the company a “buy” rating in a research report on Tuesday, April 23rd. Zacks Investment Research cut OptiNose from a “buy” rating to a “hold” rating in a research report on Thursday, July 11th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $27.00 price target on shares of OptiNose in a research report on Thursday, May 9th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. OptiNose has a consensus rating of “Buy” and an average target price of $23.30.
OptiNose Company Profile
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Featured Story: Trading Strategy Methods for Individual Investors
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.